Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
Public ClinicalTrials.gov record NCT00230035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, Phase II Multicenter Study of Non-Myeloablative Autologous Transplantation With Auto-CD34+HPC Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Systemic Lupus Erythematosus
Study identification
- NCT ID
- NCT00230035
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Autologous CD34+HPC transplantation (HSCT) Procedure
- Azathioprine Drug
- Corticosteroids Drug
- Growth colony stimulating factor (G-CSF) Drug
- Intravenous immunoglobulin Drug
- Leflunomide Drug
- Leukapheresis Procedure
- Methotrexate Drug
- Methylprednisolone Drug
- Mycophenolate mofetil Drug
- Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT) Procedure
- Plasmapheresis Procedure
- Rabbit anti-thymocyte globulin Drug
- Rituximab Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2005
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 31, 2013
Started 2005
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD, Thornton Hospital | La Jolla | California | 92037-0943 | — |
| UCLA, Rehabilitation Center | Los Angeles | California | 90095-1670 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Feinstein Institute for Medical Research NS-LIJ Health System | Manhassat | New York | 11030 | — |
| Duke University Medical Center | Durham | North Carolina | 27709 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00230035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 31, 2013 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00230035 live on ClinicalTrials.gov.